High-glucose-associated YTHDC1 lactylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

Summary: Hyperglycemia is a recognized risk factor for bladder cancer (BC). Enfortumab vedotin (EV), the first NECTIN4-targeting antibody-drug conjugate, demonstrates promising clinical efficacy in patients with advanced BC. In this study, we show that EV treatment is less effective in BC patients w...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:	Cell Reports
المؤلفون الرئيسيون:	Zhuo Xing, Tiejun Yang, Xurui Li, Haozhe Xu, Yulong Hong, Shuai Shao, Tao Li, Liefu Ye, Yuan Li, Xin Jin, Yongbao Wei
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Elsevier 2025-04-01
الموضوعات:	CP: Cancer
الوصول للمادة أونلاين:	http://www.sciencedirect.com/science/article/pii/S221112472500316X

مواد مشابهة

Desquamative extravasation reaction secondary to enfortumab vedotin
حسب: Akshay N. Pulavarty, MD, MPH, وآخرون
منشور في: (2024-04-01)

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma
حسب: Yuji Mimura, وآخرون
منشور في: (2023-03-01)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
حسب: Brigida Anna Maiorano, وآخرون
منشور في: (2023-09-01)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
حسب: Qiuji Wu, وآخرون
منشور في: (2022-01-01)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
حسب: Takamasa Homma, وآخرون
منشور في: (2023-10-01)

Enzymolysis-based RNA pull-down identifies YTHDC2 as an inhibitor of antiviral innate response
حسب: Jun Zhu, وآخرون
منشور في: (2023-10-01)

Characterizing ADRs of Enfortumab vedotin and Erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess
حسب: Yuanbin Huang, وآخرون
منشور في: (2024-12-01)

Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report
حسب: Shinji Tamada, وآخرون
منشور في: (2023-11-01)

Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma
حسب: Susanna G. Bowen, وآخرون
منشور في: (2025-09-01)

Enfortumab vedotin therapy complicated by bullous dermatitis: A case report
حسب: Roxana A. Hojjatie, BS, وآخرون
منشور في: (2025-07-01)

Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma
حسب: Toshiki Kijima, وآخرون
منشور في: (2025-01-01)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
حسب: Thibodeau A, وآخرون
منشور في: (2021-10-01)

Successful treatment with enfortumab–vedotin of metastatic signet ring cell cancer expressing nectin‐4 and originating from the bladder
حسب: Maria Aoki, وآخرون
منشور في: (2024-03-01)

Dermatitis Herpetiformis Associated with Celiac Disease Exacerbated by Enfortumab Vedotin-ejfv and Pembrolizumab
حسب: Stacy Henley, وآخرون
منشور في: (2025-01-01)

Myelodysplastic syndrome occurring after enfortumab vedotin treatment for metastatic urothelial carcinoma
حسب: Kazuki Yanagida, وآخرون
منشور في: (2024-07-01)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
حسب: Christof Vulsteke, وآخرون
منشور في: (2023-03-01)

Risk analysis of enfortumab vedotin: A real-world approach based on the FAERS database
حسب: Fuchun Zheng, وآخرون
منشور في: (2024-09-01)

Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD
حسب: Jinyang Li, وآخرون
منشور في: (2025-03-01)

The YTHDC1/GLUT3/RNF183 axis forms a positive feedback loop that modulates glucose metabolism and bladder cancer progression
حسب: Bin Yan, وآخرون
منشور في: (2023-06-01)

GCLM lactylation mediated by ACAT2 promotes ferroptosis resistance in KRASG12D-mutant cancer
حسب: Yubin Chen, وآخرون
منشور في: (2025-06-01)

Efficacy of modified enfortumab vedotin ineligible criteria (mEVITA) in advanced urothelial carcinoma
حسب: Takafumi Fukushima, وآخرون
منشور في: (2025-07-01)

Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting
حسب: Emma L. Myers, BA, وآخرون
منشور في: (2025-04-01)

Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin
حسب: John S. Wang, وآخرون
منشور في: (2025-02-01)

Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma
حسب: Keita Minami, وآخرون
منشور في: (2025-05-01)

Safety and Efficacy of Prophylactic Topical Steroid Administration for Enfortumab Vedotin–related Cutaneous Toxicity
حسب: Yuki Kita, وآخرون
منشور في: (2024-12-01)

Tumor-shrinking effects of enfortumab vedotin between primary urothelial carcinoma and metastatic organs
حسب: Daiki Ikarashi, وآخرون
منشور في: (2025-01-01)

Increased expression of ATP‐binding cassette transporters in enfortumab vedotin‐resistant urothelial cancer
حسب: Mariko Kotono, وآخرون
منشور في: (2024-03-01)

Complete Pathologic Response With Pembrolizumab and Enfortumab Vedotin in Urothelial Carcinoma of the Upper Urinary Tract
حسب: Kok Hoe Chan MD, وآخرون
منشور في: (2024-05-01)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
حسب: Jain RK, وآخرون
منشور في: (2020-09-01)

Protein lactylation of citrate synthase promotes the AKI-CKD transition by activating the NLRP3 inflammasome
حسب: Fang Yu, وآخرون
منشور في: (2025-08-01)

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States
حسب: Andong Li, وآخرون
منشور في: (2024-09-01)

Numb/Parkin-directed mitochondrial fitness governs cancer cell fate via metabolic regulation of histone lactylation
حسب: Yuman He, وآخرون
منشور في: (2023-02-01)

Lactylation orchestrates ubiquitin-independent degradation of cGAS and promotes tumor growth
حسب: Keqiang Rao, وآخرون
منشور في: (2025-04-01)

Extensive bullous lichenoid drug eruption associated with the combination therapy of enfortumab vedotin and pembrolizumab: A case report
حسب: Li-Hsin Wang, وآخرون
منشور في: (2025-01-01)

Systemic Toxicity With Hyperglycemia or Diabetic Ketoacidosis After Enfortumab Vedotin: Single-Center Case Series
حسب: Mohammad Jad Moussa, وآخرون
منشور في: (2025-05-01)

Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China
حسب: Siming Li, وآخرون
منشور في: (2024-11-01)

Lactylation prognostic signature identifies DHCR7 as a modulator of chemoresistance and immunotherapy efficacy in bladder cancer
حسب: Yuanqiao Zhao, وآخرون
منشور في: (2025-07-01)

Histone lactylation inhibits RARγ expression in macrophages to promote colorectal tumorigenesis through activation of TRAF6-IL-6-STAT3 signaling
حسب: Xiu-Ming Li, وآخرون
منشور في: (2024-02-01)

Macrophage MCT4 inhibition activates reparative genes and protects from atherosclerosis by histone H3 lysine 18 lactylation
حسب: Yunjia Zhang, وآخرون
منشور في: (2024-05-01)

Impact of Antidiabetic Medication on Therapy Outcomes in Metastatic Urothelial Cancer Patients Receiving Enfortumab Vedotin Monotherapy
حسب: Laila Schneidewind, وآخرون
منشور في: (2025-07-01)